, Volume 65, Issue 16, pp 2299–2306 | Cite as

Low-Dose Ethinylestradiol/Levonorgestrel

  • Toni M. Dando
  • Monique P. Curran
Adis Drug Profile


▴ Low-dose ethinylestradiol/levonorgestrel 20μg/ 100μg is a combined oral contraceptive that prevents pregnancy primarily by inhibiting ovulation.

▴ The Pearl index (pregnancies per 100 woman-years of use) with ethinylestradiol/levonorgestrel 20μg/ 100μg was 0.88 and the cumulative pregnancy rate was 1.9% at the end of a 3-year open-label trial (1708 women with 26 554 evaluable cycles). The contraceptive efficacy of ethinylestradiol/levonorgestrel 20μg/100μg was similar to that of other low-dose combined oral contraceptives containing ethinylestradiol 20 or 35μg in a 6-cycle trial (463 evaluable women).

▴ Ethinylestradiol/levonorgestrel 20μg/100μg is well tolerated; adverse events were those commonly associated with combined oral contraceptives. Headache and metrorrhagia (2% of women) were the most common adverse events leading to treatment discontinuation in the 3-year trial.

▴ Cycle control in open-label trials in women receiving up to 36 cycles of ethinylestradiol/levonorgestrel 20μg/100μg was generally good, with the incidence of intermenstrual bleeding being highest during the first few cycles of use and decreasing thereafter.


Oral Contraceptive Levonorgestrel Ethinylestradiol Combine Oral Contraceptive Contraceptive Efficacy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



At the request of the journal, Wyeth Pharmaceuticals Inc. provided a non-binding review of this article.


  1. 1.
    Skouby SO. Contraceptive use and behavior in the 21st century: a comprehensive studt across five European countries. Eur J Contracept Reprod Health Care 2004; 9: 57–68PubMedCrossRefGoogle Scholar
  2. 2.
    Mosher WD, Martinez GM, Chandra A, et al. Use of contraception and use of family planning services in the United States: 1982–2002. Hyattsville (MD): National Institutes of Health, National Center for Health Statistics, 2004. Advance Data From Vital and Health Statistics. Report no.: 350Google Scholar
  3. 3.
    Borgelt-Hansen L. Oral contraceptives: an update on health benefits and risks. J Am Pharm Assoc 2001 Nov; 41(6): 875–86Google Scholar
  4. 4.
    Archer DF, Maheux R, DelConte A, et al. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse®): North American Levonorgestrel Study Group (NALSG). Am J Obstet Gynecol 1999 Nov; 181: S39–44CrossRefGoogle Scholar
  5. 5.
    Wyeth Pharmaceuticals Inc. Alesse® 28 tablets (levonorgestrel and ethinyl estradiol tablets): US prescribing information 2004 Apr [online]. Available from URL: [Accessed 2005 Sep 7]
  6. 6.
    Teichmann A, Martens H, Bordasch C, et al. The effects of a new low-dose combined oral contraceptive containing levonorgestrel on ovarian activity. Eur J Contracept Reprod Health Care 1996; 1(3): 246–56CrossRefGoogle Scholar
  7. 7.
    Coney P, DelConte A. The effects on ovarian activity of a monophasic oral contraceptive with 100 μg levonorgestrel and 20 μg ethinyl estradiol. Am J Obstet Gynecol 1999 Nov; 181: S53–58CrossRefGoogle Scholar
  8. 8.
    Young RL, DelConte A. Effects of low-dose monophasic levonorgestrel with ethinyl estradiol preparation on serum lipid levels: a twenty-four month clinical trial. Am J Obstet Gynecol 1999; 181: S59–62CrossRefGoogle Scholar
  9. 9.
    Reisman H, Martin D, Gast MJ. A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 μg levonorgestrel with 20 μg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol. Am J Obstet Gynecol 1999; 181: S45–52CrossRefGoogle Scholar
  10. 10.
    Archer DF, Mammen EF, Grubb GS. The effects of a low-dose monophasic preparation of levonorgestrel and ethinyl estradiol on coagulation and other hemostatic factors. Am J Obstet Gynecol 1999 Nov; 181: S63–66CrossRefGoogle Scholar
  11. 11.
    Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low-and lower-dose oral contraceptives: a randomized trial of 20 μg and 35 μg estrogen preparations. Contraception 1999; 60: 321–9PubMedCrossRefGoogle Scholar
  12. 12.
    Carr BR, DelConte A. Using a low-dose contraceptive in women 35 years of age and over: 20 μg estradiol/100 μg levonorgestrel. Contraception 2002 Jun; 65: 397–402PubMedCrossRefGoogle Scholar
  13. 13.
    Davis AR, Westhoff C, O’Connell K, et al. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Obstet Gynecol 2005 Jul; 106: 97–104PubMedCrossRefGoogle Scholar
  14. 14.
    Coney P, Washenik K, Langley RGB, et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception 2001 Jun; 63: 297–302PubMedCrossRefGoogle Scholar
  15. 15.
    Archer DF, Maheux R, DelConte A, et al. A new low-dose monophasic combination oral contraceptive (Alesse™) with levonorgestrel 100 μg and ethinyl estradiol 20 μg: North American Levonorgestrel Study Group (NALSG). Contraception 1997 Mar; 55(3): 139–44PubMedCrossRefGoogle Scholar
  16. 16.
    The European Agency for the Evaluation of Medicinal Products. EMEA Committee for Proprietary Medicinal Products public assessment report-combined oral contraceptives and venous thromboembolism 2001 Sep 28 [online]. Available from URL: [Accessed 2005 Oct 4]
  17. 17.
    DelConte A, Loffer F, Grubb GS. Cycle control with oral contraceptives containing 20 μg of ethinyl estradiol: a multicenter, randomized comparison of levonorgestrel/ethinyl estradiol (100 μg/20 μg) and norethindrone/ethinyl estradiol (1000 μg/20 μg). Contraception 1999; 59(3): 187–93PubMedCrossRefGoogle Scholar
  18. 18.
    Chavez A, DelConte A. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 μg/20 μg versus triphasic norethindrone/ethinylestradiol 500-750-1000 μg/ 35 μg: a multicenter, randomized, open-label study. Eur J Contracept Reprod Health Care 1999 Jun; 4(2): 75-83PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Adis International LimitedMairangi Bay, AucklandNew Zealand

Personalised recommendations